Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine, Inc. - Common Stock
(NQ:
EDIT
)
1.310
-0.030 (-2.24%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Editas Medicine, Inc. - Common Stock
< Previous
1
2
3
Next >
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
December 12, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
December 09, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences
November 06, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
November 04, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Inc. (NASDAQ: EDIT) Near the Top of Equities by Percentage Gain on 2/28
February 28, 2024
Via
Investor Brand Network
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
October 22, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
October 21, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
October 18, 2024
Webinar to be held on Tuesday, October 22, at 8:00 a.m. ET
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
October 03, 2024
Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences
August 28, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
August 07, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
July 31, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
June 14, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
June 14, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
May 14, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
May 10, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces First Quarter 2024 Results and Business Updates
May 08, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
May 02, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
May 01, 2024
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
April 22, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
February 28, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
February 21, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences
January 31, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
January 08, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
2 gene-editing stocks reshaping hereditary disease treatments
January 02, 2024
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal
Via
MarketBeat
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
December 13, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
December 11, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
November 03, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
November 02, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.